Biotech | April 29, 2022
Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
Participants taking tirzepatide lost up to 52 lb. (24 kg) in this 72-week phase 3 study
The peptide-based vaccine induces a t cell-dependent response
Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
New line of Waters MaxPeak Premier columns further enhances the analysis by delivering 2x to 3x greater sensitivity than conventional steel columns
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
Under the agreement, both companies will conduct collaborative research utilizing NuclixBio's proprietary circular mRNA platform named 'ringRNA’ to develop novel mRNA therapeutics that can generate PharmAbcine's antibodies
Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally
Subscribe To Our Newsletter & Stay Updated
